BIODEXA Aktie

>BIODEXA Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>BIODEXA Aktie

Name:

BIODEXA PHARMA ADR O.N.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US59564R8079 / A40QEZ

Symbol/ Ticker:

5MP1 (Frankfurt) / BDRX (NASDAQ)

Kürzel:

FRA:5MP1, ETR:5MP1, 5MP1:GR, NASDAQ:BDRX

Index:

Webseite:

https://biodexapharma.com..

Marktkapitalisierung:

Umsatz:

EBITDA:

Gewinn je Aktie:

Schulden:

Liquide Mittel:

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

- / 0.1 / -

Gewinnm./ Eigenkapitalr.:

- / -97.23%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

BIODEXA

Letzte Datenerhebung:

06.07.25

>BIODEXA Eigentümer

Aktien: -

f.h. Aktien: -

Insider Eigner: 8.82%

Instit. Eigner: 29.86%

Leerverk. Aktien: 26.62%

>BIODEXA Peer Group

ATARA BIOTHERAPEUTICS

BIOCARDIA

CARTESIAN

DSM-FIRMENICH ADR

FORTE BIOSCIENCES

GETINGE ADR

HEALTHCARE SERVICES GROUP

PLURI

STARPHARMA ADR

XTL BIOPHARMACEUTICALS

>BIODEXA Chart & Kurs - NASDAQ

>BIODEXA News

25.06.25 - 14:33	Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) (GlobeNewswire EN)
	June 25, 2025...

23.06.25 - 14:33	Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) (GlobeNewswire EN)
	June 23, 2025...

18.06.25 - 13:06	Biodexa Pharmaceuticals: Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study (Accesswire)
	CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's imm......

04.06.25 - 14:33	Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes (GlobeNewswire EN)
	June 4, 2025...

22.05.25 - 22:33	Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting (GlobeNewswire EN)
	May 22, 2025...

22.05.25 - 14:33	Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M (GlobeNewswire EN)
	May 22, 2025...

20.05.25 - 17:30	Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here′s Why You Should Buy the Stock Now (Zacks)
	Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term....

12.05.25 - 14:33	Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP (GlobeNewswire EN)
	May 12, 2025...

24.04.25 - 19:45	What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock (Zacks)
	Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

19.03.25 - 12:06	Biodexa Pharmaceuticals PLC: With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter (Accesswire)
	CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for ......

10.03.25 - 13:33	Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP (GlobeNewswire EN)
	March 10, 2025...

06.03.25 - 14:33	Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP (GlobeNewswire EN)
	March 6, 2025...

24.02.25 - 14:33	Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use (GlobeNewswire EN)
	February 24, 2025...

13.02.25 - 14:33	Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 (GlobeNewswire EN)
	February 13, 2025...

12.02.25 - 13:39	Biodexa Pharmaceuticals PLC: Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa′s FAP Drug Receives FDA Fast Track Status (Accesswire)
	CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treat......

10.02.25 - 16:00	Biodexa stock soars 76% on FDA Fast Track status for eRapa (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.02.25 - 14:33	Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis (GlobeNewswire EN)
	February 10, 2025...

22.01.25 - 14:51	Biodexa appoints Gary A. Shangold as Chief Medical Officer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.01.25 - 14:33	Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer (GlobeNewswire EN)
	January 22, 2025...

17.01.25 - 23:06	Biodexa Pharmaceuticals files to sell 35.9M ADS for holders (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Männer sind wie Luft, zwar versaut, aber unentbehrlich. - Michelle Pfeiffer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram